GlassScriptPhysician profile
Meng Zhou Wang
NPI 1023088002
$6,022.76
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $537 · 2021: $1,146 · 2022: $1,961 · 2023: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Education: $33.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.85 |
| Education | $33.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $870.57 | 2019-2023 | Nuplazid |
| Abbvie INC. | $806.63 | 2021-2023 | Botox, Qulipta, Duopa |
| Teva Pharmaceuticals USA, INC. | $704.57 | 2019-2023 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $443.85 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $375.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $329.89 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $325.70 | 2021-2023 | Ongentys, Ingrezza |
| Emd Serono, INC. | $292.47 | 2019-2023 | Mavenclad |
| Livanova USA, INC. | $234.55 | 2019-2022 | |
| Eisai INC. | $107.04 | 2019-2023 | |
| Horizon Therapeutics Plc | $105.16 | 2022-2023 | Uplizna |
| Lundbeck LLC | $103.66 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $103.55 | 2019-2021 | |
| Pfizer INC. | $89.03 | 2023 | |
| Celgene Corporation | $86.11 | 2021-2023 | Zeposia |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meng Zhou Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.